Program Goals
Introduction
Case 1: A 44-Year-Old Woman
Definition of High-Risk Melanoma
Trials of High-Dose Interferon-Alfa
Toxicity Profile of Interferon-Alfa
Ipilimumab: EORTC 18071 Study Design
Ipilimumab: EORTC 18071 Efficacy Data
Ipilimumab: EORTC 18071 Safety Data
US Intergroup E1609 Study Design
Phase 3 Adjuvant Therapy Trials
Case 1: Conclusion
Neoadjuvant Therapy Trials
Case 2: A 54-Year-Old Man
Case 2: Treatment Options
Ipilimumab in Metastatic Melanoma
KEYNOTE-006: Study Design and Data
CheckMate 037 Trial of Nivolumab
CheckMate 067 and 069 Trials
Combined BRAF and MEK Inhibitors
Pembrolizumab in BRAF+ Melanoma
ECOG-ACRIN EA16134 Study Design
Conclusions on Anti-PD1 Antibodies
Brain Metastases in Melanoma
BREAK-MB: Phase 2 Trial of Dabrafenib
Case 3: A 65-Year-Old Man
Case 3: Managing the Patient's Colitis
Case 3: Steroid Taper
Managing Immune-Related AEs
Immunotherapy-Related Endocrinopathy
Management of Endocrinopathies
Common AEs With PD1 Inhibitors
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)